相关实验视频
Updated: May 7, 2026
12:03
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
27.8K
使用LRP1进行PCI后急性ST段升高心肌梗塞患者的术后预后评估
Jingwen Guan1, Yikang Xu1, Limin Liu1
1Cardiology Department, The Second Affiliated Hospital of Shenyang Medical College, Shenyang, China.
Frontiers in cardiovascular medicine
|March 14, 2025
概括
在ST段升高心肌梗塞 (STEMI) 患者中,低密度脂蛋白受体相关蛋白1 (LRP1) 的表达较低. 较高的LRP1水平预测穿皮冠状动脉干预 (PCI) 后的主要不良心血管事件 (MACE).
科学领域:
- 心血管医学 心血管医学
- 生物标志物发现发现
- 干预心脏病学 干预心脏病学
背景情况:
- ST段升高心肌梗塞 (STEMI) 是一种需要及时干预的危急情况.
- 确定可靠的预后标志物对于经皮冠状动脉干预 (PCI) 后管理STEMI患者至关重要.
- 低密度脂蛋白受体相关蛋白1 (LRP1) 是细胞表面受体,在心血管健康方面具有潜在的作用.
研究的目的:
- 调查低密度脂蛋白受体相关蛋白1 (LRP1) 表达的预后意义.
- 在接受PCI的STEMI患者中,评估LRP1水平与主要不良心血管事件 (MACE) 之间的关联.
主要方法:
- 这项前性研究涉及96名STEMI患者和19名对照人群.
- 通过实时定量PCR (qPCR) 在冠状动脉血液中量化LRP1表达.
- 在LRP1表达的基础上,将STEMI患者分为分层.
- 六个月的随访记录MACE.
主要成果:
- 与对照组相比,在STEMI患者中观察到明显较低的LRP1表达 (P <0.05).
- 在LRP1水平和MACE发生率之间发现了正相关性,MACE发生率在高LRP1组 (41.9%) 与低LRP1组 (6.7%) (P <0.05) 相比,MACE发生率最高.
- LRP1表达与NT-proBNP和cTnT正相关,与LVEF负相关.
- 0.79的LRP1表达值显示了81.8%的灵敏度和70%的特异性,用于预测6个月的MACE (AUC = 0.789).
结论:
- 在STEMI患者中,LRP1表达是MACE的潜在独立预测因子.
- 在STEMI中PCI后,LRP1可以作为一个有价值的预后生物标志物,用于短期结果.
- 需要进一步的研究来阐明LRP1在STEMI病理生理学中的确切作用及其临床实用性.
相关概念视频
01:30Acute Coronary Syndrome I: Introduction
2.1K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
961
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
961
01:30Acute Coronary Syndrome III: Diagnostic Studies
502
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
502
01:28Acute Coronary Syndrome IV: Interprofessional Care
528
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
528